March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Is Topical Ketorolac Tromethamine 0.4% Ophthalmic Solution Needed for Cataract Surgery? A Randomized Controlled Trial
Author Affiliations & Notes
  • Flavia G. Ticly
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Rodrigo P. Lira
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Fernando R. Zanetti
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Maria Cecília Machado
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Gustavo B. Rodrigues
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Carlos E. Arieta
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Footnotes
    Commercial Relationships  Flavia G. Ticly, None; Rodrigo P. Lira, None; Fernando R. Zanetti, None; Maria Cecília Machado, None; Gustavo B. Rodrigues, None; Carlos E. Arieta, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6683. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Flavia G. Ticly, Rodrigo P. Lira, Fernando R. Zanetti, Maria Cecília Machado, Gustavo B. Rodrigues, Carlos E. Arieta; Is Topical Ketorolac Tromethamine 0.4% Ophthalmic Solution Needed for Cataract Surgery? A Randomized Controlled Trial. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6683.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To compare effects of preoperative and postoperative use of topical ketorolac tromethamine 0.4% versus placebo in uncomplicated cataract surgery.


This was a masked single-center, randomized clinical study that comprised 46 patients undergoing phacoemulsification cataract surgery. Patients scheduled to undergo phacoemulsification and with no recognized cystoid macular edema (CME) risks (diabetic retinopathy,retinal vascular disease or macular abnormality) were randomized to receive either topical prednisolone acetate 1% 4 times daily (QID) plus dextran 70/hypromellose QID (placebo group;n=25) or topical prednisolone 1% QID plus ketorolac tromethamine 0.4% QID (ketorolac group;n=21) for three days preoperatively and four weeks postoperatively. In both groups topical gatifloxacin was administered to the treated eye QID, starting three days before surgery and continuing for seven days. The primary outcome measured on the 30th day after surgery was best corrected visual acuity (BCVA). Other outcomes included were intraocular pressure (IOP), CME incidence, retinal thickness as measured by spectral-domain optical coherence tomography (OCT).


The average age of patients were 67.88 years (SD=8.85) in placebo group versus 67.29 years (SD=12.10) in ketorolac group (P=0.849). The mean BCVA was 0.086 logmar (0.82 snellen decimal scale) in placebo group versus 0.167 logmar (0.68 snellen decimal scale) in ketorolac group (P=0.045). The mean IOP was 13.08 mmHg (SD=2.66) in placebo group versus 13.05 mmHg (SD=2.85) in ketorolac group (P=0.968). No patient had clinically significant CME. One (4%) patient in the placebo group and two (9.52%) patients in the ketorolac group had angiographic CME (P=0.584). Mean retinal thickening was 228.56µm (SD=24.95) in the placebo group versus 224.86µm (SD=22.33) in the ketorolac group (P=0.602).


This study suggests that there is no need to add ketorolac tromethamine 0.4% ophthalmic solution to routine cataract surgery.

Clinical Trial: NCT00865540

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • macula/fovea • cataract 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.